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A nitroreductase and glutathione responsive
nanoplatform for integration of gene delivery
and near-infrared fluorescence imaging†
Hong Liang,‡a Qunjie Bi,‡a Ao Hu,a Xiaobing Chen,a Rongrong Jin,a Xu Song,*ab
Bowen Ke, a Matthias Barz c and Yu Nie *a
A novel platform rationally integrating indocyanine green analogues
and an arginine-rich dendritic peptide with both nitroreductase (NTR)
and glutathione (GSH) reduction responsive linkers was developed.
This multifunctional platform can enable selective and efficient gene
delivery and specific turn-on fluorescence imaging in tumors.
Tumor cells, tumor associated cells, and cellular and extracellular
matrix components constitute an orchestrated ‘‘tumor micro-
environment’’, promoting the growth, invasion and metastasis
of tumors.1 A hallmark of solid tumor microenvironments is
hypoxia, originating from an insufficient oxygen supply from
the blood due to disorganized vasculature.2 Hence, the bio-
markers of hypoxia, such as overexpressed reductive enzymes
(including glutathione, nitroreductase, azoreductase and
DT-diaphrose),3–5 could be useful for tumor diagnosis and
antitumor treatment.6,7 Among them, NTR switchable fluoro-
phores have received a lot of attention due to their exceptional
sensitivity.8–11 A combination of fluorescence recovery with
chemotherapy, photodynamic therapy and radiotherapy12,13
has achieved rapid development as a theranostic platform.
However, tumor hypoxia is also known as the ‘‘Achilles’ heel’’
of traditional photodynamic therapy (PDT), because severe
tumor hypoxia hampers therapeutic outcomes of oxygen-
dependent PDT and PDT potentiates hypoxia.
Gene therapy is a promising treatment which works by
silencing abnormally overexpressed genes or compensating
for defective genes,14,15 which has no conflict with the hypoxic
conditions. This might be a good choice for the NTR triggered
theranostic therapy. In particular, visual tracing of genes gives
an intuitive and quantitative evaluation of the dynamic delivery
processes at both the cellular and tissue levels in a real-time
fashion.16,17 It is generally known that direct labeling of genes
could influence their biological effect, the probes are usually
physically encapsulated or chemically bonded to the periphery
of the nanocarriers. However, these loading methods for fluor-
escent nanomaterials often suffer from premature leakage.18,19
Thus, an integrated fluorescent probe, consisting of boron-
dipyrromethene (BODIPY) as the main component has been
designed as a drug carrier,20 and PEGylated platinated-BODIPY
molecules have been developed to combine chemical, photo-
dynamic and photothermal therapies together for tumor
ablation.21 Our previous work has proved that arginine-rich
amphiphilic lipopeptides exhibit excellent gene transfection
activity,22–24 and microenvironment-responsive modification
could strongly promote both specificity and efficiency of gene
expression.25,26 Our recent investigations further confirm that
dual or multi-responsive triggers in carrier design provided a
deeper biological understanding of the tumor micro-environment,
and resulted in high-specific, highly efficient and low-toxic
therapy.27,28 The high GSH concentration (at least 4 fold higher) is
one of the important characteristics that distinguish tumor tissue/
cells from normal tissue/cells.29,30 Therefore, we intend to utilize the
feature of high concentration of NTR and GSH around the tumor
and intra-tumor cells simultaneously. Accordingly, a NTR-sensitive
near-infrared fluorescent molecule was designed as the hydro-
phobic segment, whose fluorescence would be quenched due to
photoinduced electron transfer.31–33
We herein developed NTR and GSH-induced ‘‘turn-on’’ assem-
blies (RNNS) for gene delivery and targeted imaging with real-time
visualization of carrier metabolism (Scheme 1). The carriers
possess an arginine-rich hydrophilic moiety for efficient gene
condensation and cytomembrane penetration, a derivative of
cyanine dye, in the skeleton of the amphiphilic molecule as the
hydrophobic moiety for NTR-sensitive fluorescence imaging, and a
disulfide bond as the trigger for GSH-responsive cargo release in
tumor sites.
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The synthetic route to the target RNNF molecule and details
are presented in Fig. S1 (ESI†), and the structure characteriza-
tion of each molecule has been performed through nuclear
magnetic resonance spectroscopy (NMR) and MS (Fig. S2–S13,
ESI†). The amphiphilic RNNF molecule could self-assemble
into nano-sized assemblies with a Z-average size of 340 nm
and a zeta potential of +29 mV. It could also be mixed with
another amphiphilic molecule (RLS) synthesized in our pre-
vious work23 at different molar ratios (1/1, 1/2 and 1/3) to obtain
smaller assemblies (RNNS, size from 130–185 nm) with better
size distribution. RNNS-3 assemblies (RNNF/RLS, molar ratio =
1/3) showed a minimum size of 136 nm with a positive charge
(+22 mV) (Table S1, ESI†). The larger diameter might be
ascribed to both strong hydrophobicity and rigidity of the
fluorescent molecule (RNNF) during self-assembly.34–36 While
the addition of the flexible RLS molecule might be conducive to
its tight integration with molecules, it results in smaller size of
the assembly.23 The size of all assemblies increased after DNA
condensation, and the zeta potential reduced slightly. As a
representative, the morphology of RNNS-3 assemblies and
RNNS-3/DNA complexes were observed through transmission
electron microscopy (TEM). RNNS-3 assemblies showed a uni-
form discoid shape and RNNS-3/DNA complexes revealed a
uniform ellipsoidal shape (Fig. 1A and B). The fluorescence
spectral characteristics of various molecules and assemblies in
organic or aqueous solutions were investigated to detect the
on-demand ‘‘OFF’’ and ‘‘ON’’ signals, respectively (Fig. 1C).
RNNF showed no fluorescence signal in organic solution, even
after incubation with GSH. While the spectral peak significantly
enhanced in the presence of both NTR and NADH. This
indicated specific response of RNNF molecules to NTR with
an outstanding turn-on effect on fluorescence recovery, which
might be beneficial for reducing the background interference.
In order to evaluate the selective disassembly response of
assemblies, RLS, RNNF, and RNNS-1, 2, 3 and 4 were incubated
with GSH, NTR or their mixture, respectively. The changes in
the size and zeta potential are shown in Fig. 2A–C and Fig. S14
(ESI†). RLS and RNNF displayed the most rapid increase in
size when incubated with GSH and NTR, respectively. While
RNNF/RLS assemblies showed relatively slow responses in the
presence of GSH or NTR. It might be that RNNF partly prevented
the degradation of RLS by GSH, and RLS also disturbed the
interaction between RNNF and NTR. What’s more, noticeable
Scheme 1 The NTR and GSH responsive nanoplatform for gene delivery
and fluorescence imaging.
Fig. 1 Characterization of RNNS-3 assemblies and RNNS-3/DNA com-
plexes by TEM and fluorescence spectra of RNNF in various solutions. TEM
image of RNNS-3 assemblies (A) and RNNS-3/DNA complexes (B), respectively.
(C) Fluorescence spectra of RNNF in various solutions with maximal excitation
wavelength (dotted line, Ex 690 nm) and emission wavelength (solid line, Em
870 nm), respectively. Black lines: RNNF in methanol, red lines: RNNF in mixed
solution (methanol/water, 1/1, v/v) with 10 mM GSH for 2 h, blue lines: RNNF
in mixed solution (methanol/water, 1/1, v/v) with 5 mg mL1 NTR and 1 mM
NADH for 2 h.
Fig. 2 The selective disassembly response and corresponding gene
release of various assemblies in different conditions. The changes of size
for various assemblies (RNNF, RLS and RNNS) after incubation with 10 mM
GSH (A), 5 mg mL1 NTR and 1 mM NADH (B), or mixture of GSH and NTR
(C), respectively. Date are presented as means  SD (n = 5). (D) The gene
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changes in the size and zeta potential of all assemblies were
observed in the presence of both GSH and NTR, revealing the
successful disassembly.
Some research has found that assemblies with a rigid
structure could be conducive to forming tight interaction with
the cargo and improve their gene condensation ability.35,36 Thus,
we evaluated the gene compaction ability of various assemblies
with different N/P ratios through gel electrophoresis (Fig. S15A,
ESI†) and RNNS-3 was chosen as a representative for mixed
assemblies. It was clear that pDNA could be completely dragged
in the loading position by RLS at an N/P ratio of 60, by RNNF at an
N/P ratio of 20 and by RNNS-3 at an N/P ratio of 30, respectively.
RNNF with a relatively rigid structure really showed benefit for the
condensation, and its addition could contribute to gene compac-
tion with lower N/P in the mixed assemblies. Consequently, gene
release ability of these assemblies was investigated in the presence
of GSH, NTR or their mixture, respectively (Fig. 2D and Fig. S15B,
ESI†). The images showed that in the presence of either GSH
or NTR alone, the release of gene in RNNF, RLS and RNNS
assemblies was incomplete. This revealed that fluorescence could
recover in NTR solution but without gene release (Fig. 1). However,
all the assemblies could completely release the gene in the mixture
of GSH and NTR.
Although it has been reported that the content of NTR is
relatively high in tumor cells due to the hypoxic environment,37
there is hardly any relevant data to support this statement.8–11
Therefore, the content of NTR in tumor cells (HeLa) and non-
tumor cells (human umbilical vein endothelial cells, HUVEC)
were detected using a Human NTR ELISA Kit, which indeed
showed higher NTR content in HeLa cells than that in HUVEC
(Fig. S16, ESI†). In addition, GSH has also been confirmed to be
highly expressed in HeLa cells.22,38 Subsequently fluorescence
recovery of RNNS-3 gene complexes was studied in HeLa cells
with HUVEC as a control (Fig. 3A). It was obviously found that the
fluorescent signal in HeLa cells gradually enhanced with the
incubation time, while only slight changes were observed in
HUVEC. The semi-quantitative evaluation also confirmed these
results, showing almost 5-fold difference in intensity (Fig. S17,
ESI†). We could speculate that the fluorescence of RNNS-3 could
recover upon interaction with NTR and GSH in HeLa cells.
In vitro gene transfection activity of these assemblies was
also studied on HeLa cells, and pEGFP plasmid acted as the
model gene (Fig. 3B and Fig. S18, ESI†). More green fluorescent
spots were observed in the RNNS-3 group compared to the PEI
or lipofectamine 2000 group, either in the presence or absence
of 10% FBS. In the culture medium with 10% FBS, the gene
transfection activity of these mixed assemblies decreased to a
certain extent, but still far surpassed that of the control groups
(Fig. 3B and Fig. S18, ESI†). RNNS-3 assemblies showed the best
gene transfection effect at N/P = 30, reaching up to 30-fold
higher than commercial reagents (lipofectamine 2000 and PEI).
Flow cytometry data also confirmed that RNNS-3 (N/P = 30)
retained a high gene expression in HeLa cells with 10% serum
(Fig. S19, ESI†). The gene transfection efficiency would be gradu-
ally improved with an increase in the ratio of RNNF. But excessive
rigidity would obstruct the interaction between the nanocarriers
and cell membrane, and even hinder endocytosis and gene
release.39 Meanwhile, cytotoxicity is another factor that influences
the gene transfection effects, and might lead to the poor gene
transfection efficiency of RNNS-1 (Fig. S20, ESI†). The order of
cytotoxicity for these assemblies was RNNS-1 4 RNNS-2 4
RNNS-3 4 RNNS-4. Almost no toxicity was observed in RNNS-3
groups at concentrations below 60 mg mL1, which was suitable for
in vitro and in vivo applications. According to our previous works,
RLS showed very low cytotoxicity.22–24 We speculated that cytotoxi-
city was mainly caused by RNNF. The addition of RLS has
significant neutralizing effect on the rigidity of RNNF, thus redu-
cing the cytotoxicity of mixed assemblies. As a result, the RNNS-3
assemblies with a partly rigid structure and low cytotoxicity show
the best performance of gene transfection in culture medium with
or without FBS.
In the animal experiment, RNNS-3/pEGFP showed a turn-on
effect at the tumor site (Fig. S21, ESI†). The near-infrared (NIR)
strong fluorescence was maintained for 6 h post-injection, as
shown in the living mice image (Fig. S21A, ESI†) and ex vivo image
of the isolated tissues (Fig. S21B, ESI†). Images also reflected that
the indocyanine green (ICG) analogs degraded from RNNS-3 could
be metabolized by the liver and excreted through the kidneys.40
Fig. 3 Fluorescence recovery and in vitro gene transfection efficiency of
RNNS-3. (A) Fluorescence recovery image of RNNS-3 observed through a
laser scanning confocal microscope (CLSM). The plasmid DNA was
condensed by RNNS-3 assemblies at N/P = 30. HeLa (tumor cells) and
HUVEC (non-tumor cells) were incubated with the RNNS-3/DNA com-
plexes for different times (1, 2, 4 and 6 h). The fluorescence signals (red)
were observed under 663 nm laser-excitation and 700–800 nm emission
signals. Scale bar = 100 mm. (B) Fluorescence microscopy images of HeLa
cells with EGFP transfection for 48 h in the culture medium without or with
10% FBS. pEGFP plasmid DNA were condensed by RNNS-3 assemblies at
different N/P ratios (N/P = 20, 30, 40 and 60). Lipofectamine 2000 and PEI
(MW = 25 000) acted as control groups. The N/P ratio of PEI/DNA
complexes were 10.22–24 Liposome 2000/DNA complex was 0.2 mL/100
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This result confirmed that RNNS-3 could be degraded or metabo-
lize and is safe for humans. In vivo gene transfection was studied
48 h post-injection (Fig. 4). Compared with the PEI/pEGFP group,
the frozen sections of isolated tumors in the RNNS-3/pEGFP group
showed considerable green fluorescence which agreed well with
the result of the NIR channel, indicating that NIR provide the
accurate location of gene expression in the tumor site.
In summary, we designed a type of amphiphilic lipopeptide
molecule, RNNF, which could be used as a theranostic nano-
platform for cancer treatment through self-assembly. The
mixed assemblies RNNS-3 (RNNF/RLS = 1/3) have a minimum size
of 136 nm and their fluorescence showed NTR-responsiveness with
the maximum emission wavelength at 870 nm. Although RNNF
and RLS assemblies show different sensitive responsiveness to
NTR and GSH respectively, RNNS-3 assemblies showed good
responsiveness to both and good gene condensation and
release ability in the presence of NTR or GSH. Moreover,
with low cytotoxicity, RNNS-3 exhibited excellent fluorescence
recovery and efficient gene transfection performance both
in vitro and in vivo. Their gene transfection activity was even
much better than commercial reagents such as lipofectamine
2000 and PEI (MW = 25 000).
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